At GBA Pharma, we have broad experience in handling small molecules as well as larger molecules, biologics and cell based therapies. We can support your projects from early lead optimization and early preclinical stage to clinical studies with our GMP Depots, EU GMP manufacturing site for labelling and packaging and QP services, as well as late drug development and analytical services including import testing and QP batch release.
For nearly 20 years the GBA site at Saarbrücken leverages the expertise of our highly qualified team to provide tailor-made drug discovery & development solutions. We offer GLP and non-GLP studies for exploratory or regulatory demands. Our portfolio covers in vitro, in vivo, ex vivo and bioanalytical services. › more
Our locations for analytical services support you in the development, approval process, and quality control of your products with an extensive range of services. › more
We focus on complex clinical trial designs and offer a unique combination of logistic services through our global network. It is precisely this flexibility and personal approach that differentiates us from our competitors. › more
GBA Pharma was formed by mergers of five formerly independent companies located in Germany and Austria: Pharmacelsus GmbH (Saarbrücken), Phytos Labor für Analytik von Arzneimitteln GmbH & Co. KG (Neu-Ulm), LPU Labor für Pharma- und Umweltanalytik GmbH (Martinsried, Gräfelfing), and ABF Pharmaceutical Services GmbH (Vienna). Our clients range from pharmaceutical and biotechnology companies to service providers; contract research and contract manufacturing organizations and academic institutions. The Headquarter of GBA Pharma division is located in Martinsried (Munich area); one of the hot spots of pharmaceutical and biotechnology in Europe. All German sites are operating as branches of GBA Pharma GmbH and our Austrian site is a hundred percent subsidiary called GBA Pharma Austria GmbH.
All merged companies have one key characteristic in common: stable and trusting long-standing relationships with our clients. This is result of the high quality of services, reliable timelines, state of the art portfolio of methods and equipment combined with academic resilience to solve problems.
We have extensive experience in the pharmaceutical industry. Each of our subsidiaries have an operational experience of 12 to 38 years. Majority of our staff are academically educated to post-graduate level. 90% annual repeat business is a testimony of our emphasis on becoming a trusted extension of your team and facilitation your success by delivering high quality services combined with an outstanding scientific expertise.
Our services are divided into four categories:
In the mentioned fields we are working in strict compliance with the regulatory requirements, such as but not limited to:
17. - 18. October 2017
Bio Investor Forum, San Francisco
24. - 26. October 2017
Hall 4, Stand C35
06. - 08. November 2017
Bio Europe, Berlin